Anaphylaxis and Cardiac Arrest Management

Indications for Epinephrine Administration

The American Academy of Allergy, Asthma, and Immunology recommends epinephrine as the first-line treatment in all cases of anaphylaxis, with no substitute or alternative first-line medication 1
The American Academy of Allergy, Asthma, and Immunology suggests administering epinephrine as soon as possible once anaphylaxis is recognized, even if there is any doubt about the diagnosis 2
Delays in instituting therapy with epinephrine are associated with increased risks of death and morbidity, according to the American Academy of Allergy, Asthma, and Immunology 1
The American Heart Association recommends administering epinephrine as soon as feasible after the onset of cardiac arrest with a nonshockable rhythm 3
The American Heart Association suggests that for cardiac arrest with a shockable rhythm, it may be reasonable to administer epinephrine after initial defibrillation attempts have failed 3
Patients with a history of severe anaphylactic reactions, particularly those with asthma, are at higher risk of fatal anaphylaxis and should have immediate access to epinephrine, as stated by the American Academy of Allergy, Asthma, and Immunology 1, 2
Schools present a special hazard for students with food allergies; epinephrine should be available for use by individuals trained to respond to such emergencies, according to the American Academy of Allergy, Asthma, and Immunology 2
The American College of Cardiology states that earlier administration of epinephrine in cardiac arrest is associated with improved outcomes compared to later administration 3
The American Heart Association recommends that for nonshockable rhythms, administer epinephrine as soon as vascular access is established 3, 4
Patients with cardiovascular disease should still receive epinephrine for anaphylaxis, as the risk of a life-threatening anaphylactic reaction exceeds the risk of adverse effects, according to the American Academy of Allergy, Asthma, and Immunology 5
Medical facilities should have established protocols to deal with anaphylaxis and cardiac arrest, with appropriate equipment readily available, as recommended by the American Academy of Allergy, Asthma, and Immunology 2

Adrenaline Administration Guidelines

Cardiac Arrest Management

For refractory cardiac arrest cases, the American Academy of Pediatrics recommends an epinephrine infusion prepared by adding 1 mg of 1:1000 solution to 250 mL of D5W to yield 4.0 μg/mL, infused at 1-4 μg/min, increasing to a maximum of 10.0 μg/min if needed 6
In pediatric cardiac arrest, the American Heart Association recommends IV/IO administration of 0.01 mg/kg (0.1 mL/kg of 1:10,000 solution), with a maximum single dose of 1 mg 7

Pediatric Dosing Considerations

For continuous infusion in pediatric patients, the "rule of 6" can be applied: 0.6 × body weight (kg) = mg diluted to 100 mL of saline; then 1 mL/h delivers 0.1 μg/kg/min, as suggested by the American Academy of Pediatrics 8

Route of Administration

The American Academy of Allergy, Asthma, and Immunology recommends intramuscular injection over subcutaneous injection for anaphylaxis, as it provides a more rapid increase in plasma and tissue concentrations 9
The anterolateral thigh (vastus lateralis muscle) is the recommended site for intramuscular injection, according to the American Academy of Allergy, Asthma, and Immunology 9
IV administration (1:10,000 solution) should be reserved for cardiac arrest or severe shock unresponsive to intramuscular epinephrine and fluid resuscitation, as recommended by the American Society of Anesthesiologists 10

Important Cautions and Preparations

The American Academy of Pediatrics emphasizes the importance of verifying the correct concentration before administration - 1:1000 (1 mg/mL) for intramuscular use and 1:10,000 (0.1 mg/mL) for IV use, to avoid potentially fatal overdose 11
For cases requiring continuous infusion, an alternative 1:100,000 solution (1 mg in 100 mL saline) can be prepared and administered at 30-100 mL/h (5-15 μg/min), as recommended by the American Academy of Allergy, Asthma, and Immunology 6

Anaphylaxis Treatment Guidelines

Primary Indications for EpiPen Use

The American Academy of Pediatrics recommends using an EpiPen immediately at the first signs of anaphylaxis, particularly when respiratory or cardiovascular symptoms are present, or when there is known exposure to an allergen that previously caused anaphylaxis, even if symptoms are still mild 12
Respiratory symptoms such as difficulty breathing, wheezing, shortness of breath, throat tightness, or stridor indicate the need for immediate EpiPen use in patients with a history of anaphylaxis 12, 13
Cardiovascular symptoms, including hypotension, dizziness, fainting, or loss of consciousness, require immediate EpiPen administration in individuals with known severe allergies 12
Skin manifestations with other systemic symptoms, such as widespread hives, flushing, itching, or angioedema, especially when accompanied by symptoms affecting other organ systems, necessitate EpiPen use 13, 14
Gastrointestinal symptoms like severe abdominal pain, persistent vomiting, or diarrhea, particularly when occurring with other symptoms, indicate the need for EpiPen administration 13
Known allergen exposure in someone with previous anaphylaxis, even if symptoms are initially mild, requires immediate EpiPen use 12, 13

Special Circumstances Requiring Immediate EpiPen Use

Generalized acute urticaria after exposure to a known allergen that previously triggered anaphylaxis necessitates immediate EpiPen use 12, 15
Symptoms after an insect sting in someone with previous systemic reactions, even if initially only skin symptoms are present, require EpiPen administration 16, 17
Rapid progression of symptoms after exposure to foods commonly associated with severe reactions, such as peanuts, tree nuts, seafood, or milk, indicates the need for immediate EpiPen use 13, 15
Any symptoms in someone with asthma and known severe allergies require immediate EpiPen administration, as they are at higher risk of fatal anaphylaxis 12

Decision-Making Algorithm

The American Academy of Pediatrics suggests that if there has been exposure to a known allergen trigger and previous anaphylaxis to this trigger, an EpiPen should be used immediately 12, 13
If symptoms such as difficulty breathing, wheezing, throat tightness, dizziness, fainting, low blood pressure, widespread hives with other systemic symptoms, severe abdominal pain, or persistent vomiting are present, an EpiPen should be used immediately 12, 13, 14, 18, 19
Special risk factors, including asthma with allergic reaction, previous severe reactions, or exposure to high-risk allergens, lower the threshold for EpiPen use 12, 13, 14

Common Pitfalls to Avoid

Delaying epinephrine administration is associated with increased mortality and morbidity, emphasizing the importance of prompt EpiPen use 14
Relying on antihistamines or inhalers is not a substitute for epinephrine in anaphylaxis, as stated by the American Academy of Pediatrics 14
Assuming mild symptoms will remain mild is incorrect, as anaphylaxis can progress rapidly and unpredictably 13
Fear of using the EpiPen shouldn't prevent its administration, as the risks of untreated anaphylaxis far outweigh the risks of appropriate epinephrine use 14

When in Doubt

If uncertain whether symptoms represent anaphylaxis, err on the side of using the EpiPen, as recommended by the American Academy of Pediatrics 13, 14
Even experienced physicians cannot predict which reactions will remain mild and which will become life-threatening, highlighting the need for prompt EpiPen use 13, 15
After using an EpiPen, seek immediate medical attention, as symptoms may return and additional treatment may be needed 13

Administration Considerations

Positioning the person lying flat with legs elevated if experiencing dizziness or low blood pressure, unless they are having breathing difficulties, is recommended 19
Epinephrine is the first-line treatment for anaphylaxis, and there is no contraindication to using epinephrine when anaphylaxis is suspected, as stated by the Journal of Allergy and Clinical Immunology 18

Anaphylaxis Treatment with Intramuscular Adrenaline

Administration Technique

The American Academy of Pediatrics recommends injecting adrenaline into the anterolateral aspect of the mid-thigh (vastus lateralis muscle) to achieve peak plasma concentrations in 8±2 minutes, compared to 34±14 minutes with subcutaneous deltoid injection 20, 21
Insertion of the needle at a 90-degree angle ensures intramuscular delivery, as recommended by the American Academy of Pediatrics 20

Critical Safety Points

The American Academy of Pediatrics and the Journal of Allergy and Clinical Immunology recommend never using the subcutaneous route, as intramuscular injection in the thigh is superior and provides more rapid, higher peak plasma levels 20, 22
The American Academy of Pediatrics and the Journal of Allergy and Clinical Immunology advise against intravenous administration in first-aid settings, as it carries significant risk of dilution/dosing errors and serious adverse effects 20, 21, 22

Contraindications and Monitoring

The Journal of Allergy and Clinical Immunology states that there is no absolute contraindication to epinephrine in anaphylaxis, as the risk of death from untreated anaphylaxis far exceeds any risk from epinephrine 22
The Journal of Allergy and Clinical Immunology recommends monitoring clinically for severity of allergic reaction and potential cardiac effects, including assessing respiratory status, blood pressure, and level of consciousness 22

Common Pitfalls to Avoid

The American Academy of Pediatrics recommends avoiding the use of the deltoid or subcutaneous route, as it results in delayed absorption and suboptimal treatment 20, 21

Anaphylaxis Treatment Guidelines

Primary Route Selection

The American Heart Association recommends IM epinephrine as the initial treatment for anaphylaxis, with a Class 1 (strong) recommendation, stating that epinephrine should be administered early by intramuscular injection to all patients with signs of a systemic allergic reaction 23.
IM epinephrine is universally recommended as the first-line treatment for anaphylaxis, regardless of IV access availability, due to its safer and more favorable risk-benefit profile compared to IV epinephrine 23, 24, 25.

Safety Profile Comparison

IM administration has a well-established safety profile with minimal risk of serious adverse effects when given at standard doses, and there are no absolute contraindications to IM epinephrine for anaphylaxis, including in patients with cardiac disease or those on beta-blockers 23, 25, 26.
IV epinephrine carries significant risks, including medication errors, cardiac complications, and the requirement for precise titration, making it a less preferred option for initial treatment 23, 25.

Practical Implementation

The recommended dose for IM epinephrine is 0.3-0.5 mg for adults and 0.01 mg/kg for children, administered in the anterolateral thigh, and can be repeated every 5-15 minutes as needed if symptoms persist or recur 23, 25, 26.
IV epinephrine should only be used when IM epinephrine has failed to control symptoms, or in cases of profound refractory shock, with a recommended dose of 0.05-0.1 mg given as a slow IV push or continuous infusion 23, 25.

Epinephrine Administration in Anaphylaxis

Introduction to Anaphylaxis Treatment

The American Heart Association recommends that every patient with anaphylaxis requires immediate epinephrine administration, regardless of whether respiratory compromise is present 27, 28
Anaphylaxis is a multisystem disorder where only approximately 70% of patients present with respiratory symptoms, and only 10% experience cardiovascular symptoms initially, emphasizing the need for prompt epinephrine administration 29

Clinical Presentation and Epinephrine Administration

Cutaneous manifestations (urticaria, angioedema, flushing) occur in over 80% of anaphylaxis cases, and the absence of respiratory symptoms does not exclude the need for epinephrine 29
The American Academy of Pediatrics states that symptoms not immediately life-threatening can progress rapidly to become fatal, highlighting the importance of timely epinephrine administration 28, 30

High-Risk Populations and Administration Guidelines

Patients with concurrent asthma are at significantly higher risk of fatal anaphylaxis and should receive epinephrine even more promptly, according to the American Academy of Pediatrics 31
The American Academy of Otolaryngology-Head and Neck Surgery recommends that intramuscular injection into the anterolateral thigh (vastus lateralis) is the required route for epinephrine administration, with a dose of 0.3-0.5 mg of 1:1000 solution for adults and 0.01 mg/kg for pediatric patients 32

Post-Administration Management and Safety Considerations

The American Heart Association advises activating emergency medical services immediately after epinephrine administration and preparing for repeat dosing, as 7-18% of patients require a second dose 27
The American Academy of Pediatrics recommends observing patients for biphasic reactions and extended observation is needed for severe cases or those requiring multiple doses 32